However, after TLR4 activation was suppressed in the LPS-RS group, the heart function declined and ventricular dilatation was alleviated compared with the control group (EF: 67 ± 6.1% versus 54 ± 8.2%, p < 0.05; FS: 37 ± 6.2% versus 30 ± 7.0%, p < 0.05; LVEDD: 3.1 ± 0.39 mm versus 3.8 ± 0.53 mm, p < 0.05; LVEDV: 44.1 ± 7.6 μL versus 56.5 ± 8.7 μL, p < 0.05) (Figures 1(a), 1(d), and 1(e)). Here, TLR4 is linked to Ventriculomegaly.